Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DERRICK S ROBERTSON

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1912169376
CMS profile
86427
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$310,505.18

267 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 267 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DERRICK S ROBERTSON

NPI 1912169376 · CMS profile ID 86427

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 267 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912169376?year=2022&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DERRICK S ROBERTSON, NPI 1912169376, CMS profile ID 86427. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 267 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912169376?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DERRICK S ROBERTSON, NPI 1912169376, CMS profile ID 86427. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 267 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912169376?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DERRICK S ROBERTSON, NPI 1912169376, CMS profile ID 86427, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 267 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1912169376?year=2022&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

267 matching records · $310,505.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 267 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 267.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $3,080.0008/12/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941549525 CMS
Horizon Therapeutics plc $35.4008/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682315 CMS
E.R. Squibb & Sons, L.L.C. $107.6908/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586505 CMS
EMD Serono, Inc. $60.2608/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941547893 CMS
EMD Serono, Inc. $3.2208/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941547917 CMS
Horizon Therapeutics plc $3,598.0008/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682309 CMS
Biogen, Inc. $3,065.0008/04/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923463245 CMS
EMD Serono, Inc. $95.9308/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941545851 CMS
EMD Serono, Inc. $3,080.0008/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941545271 CMS
Horizon Therapeutics plc $113.6407/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682305 CMS
Biogen, Inc. $24.3807/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923429689 CMS
E.R. Squibb & Sons, L.L.C. $72.7207/20/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586433 CMS
E.R. Squibb & Sons, L.L.C. $44.4307/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586437 CMS
Biogen, Inc. $3,065.0007/19/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923408473 CMS
GENZYME CORPORATION $95.0907/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024471 CMS
GENZYME CORPORATION $5,085.0007/14/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024473 CMS
GENZYME CORPORATION $698.7507/14/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024475 CMS
E.R. Squibb & Sons, L.L.C. $9.8907/13/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586421 CMS
Janssen Pharmaceuticals, Inc $1,350.0007/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886013343 CMS
Horizon Therapeutics plc $400.0007/06/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682301 CMS
E.R. Squibb & Sons, L.L.C. $4,030.0006/29/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586431 CMS
Horizon Therapeutics plc $3,598.0006/28/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682293 CMS
Horizon Therapeutics plc $9.2406/28/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682297 CMS
Horizon Therapeutics plc $82.1106/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682287 CMS
E.R. Squibb & Sons, L.L.C. $4,030.0006/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586419 CMS
Horizon Therapeutics plc $1,621.5006/21/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682283 CMS
Genentech USA, Inc. $240.7506/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662433 CMS
EMD Serono, Inc. $3,080.0006/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941525575 CMS
Genentech USA, Inc. $88.3306/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662377 CMS
Genentech USA, Inc. $47.9306/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662385 CMS
Genentech USA, Inc. $240.7506/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662473 CMS
Genentech USA, Inc. $292.5106/10/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662503 CMS
Genentech USA, Inc. $7,935.0006/10/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950662545 CMS
E.R. Squibb & Sons, L.L.C. $495.8806/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586429 CMS
E.R. Squibb & Sons, L.L.C. $480.8006/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586435 CMS
E.R. Squibb & Sons, L.L.C. $9.2406/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586403 CMS
E.R. Squibb & Sons, L.L.C. $4,030.0006/08/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586513 CMS
E.R. Squibb & Sons, L.L.C. $27.4406/08/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586515 CMS
Horizon Therapeutics plc $125.0006/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937682279 CMS
Celgene Corporation $93.9306/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586397 CMS
E.R. Squibb & Sons, L.L.C. $175.6806/06/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586417 CMS
GENZYME CORPORATION $82.5106/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024331 CMS
Biogen, Inc. $93.7306/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923440421 CMS
E.R. Squibb & Sons, L.L.C. $4,030.0006/02/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586411 CMS
EMD Serono, Inc. $32.5006/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941521755 CMS
Novartis Pharmaceuticals Corporation $52.7606/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894288597 CMS
GENZYME CORPORATION $2,000.0005/30/2022 Grant No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024339 CMS
Biogen, Inc. $1,839.0005/26/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923440417 CMS
E.R. Squibb & Sons, L.L.C. $9.9505/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586401 CMS
E.R. Squibb & Sons, L.L.C. $79.9005/24/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932586415 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $210,383.19 273
PY2020 $159,278.56 144
PY2021 $247,256.02 201
PY2022 $310,505.18 267
PY2023 $316,039.15 264
PY2024 $312,735.46 256
PY2025 $264,593.78 263

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,816.00 5
PY2025 Principal investigator $3,729,878.43 335
PY2024 Recipient $6,611.42 4
PY2024 Principal investigator $4,362,119.33 345
PY2023 Recipient $2,409.44 1
PY2023 Principal investigator $3,958,615.27 304
PY2022 Recipient $12,505.75 5
PY2022 Principal investigator $4,165,232.40 243
PY2021 Recipient $3,234.65 7
PY2021 Principal investigator $4,173,766.35 213
PY2020 Recipient $5,850.52 6
PY2020 Principal investigator $2,797,874.16 135
PY2019 Principal investigator $2,555,209.31 143

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

340 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,005.92 12/24/2025 Non-covered Recipient Entity
Usf
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235992081
Principal investigator 1 GENZYME CORPORATION $1,296.00 12/22/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226080320
Principal investigator 1 GENZYME CORPORATION $650.00 12/22/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226080325
Principal investigator 1 F. Hoffmann-La Roche AG $7,669.00 12/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670153
Principal investigator 1 Genentech, Inc. $3,033.00 12/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670731
Principal investigator 1 TG Therapeutics, Inc. $595.00 12/19/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198489
Principal investigator 1 TG Therapeutics, Inc. $455.00 12/19/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199399
Principal investigator 1 GENZYME CORPORATION $4,510.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141225
Principal investigator 1 GENZYME CORPORATION $135.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141228
Principal investigator 1 GENZYME CORPORATION $320.40 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141236
Principal investigator 1 GENZYME CORPORATION $650.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141241
Principal investigator 1 GENZYME CORPORATION $124,209.05 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141244
Principal investigator 1 GENZYME CORPORATION $1,065.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141249
Principal investigator 1 GENZYME CORPORATION $320.40 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141253
Principal investigator 1 GENZYME CORPORATION $213.60 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141256
Principal investigator 1 GENZYME CORPORATION $3,500.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141266
Principal investigator 1 GENZYME CORPORATION $7,529.40 12/15/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141282
Principal investigator 1 GENZYME CORPORATION $23,769.05 12/15/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141286
Principal investigator 1 GENZYME CORPORATION $3,430.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141290
Principal investigator 1 GENZYME CORPORATION $2,295.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141297
Principal investigator 1 GENZYME CORPORATION $1,450.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141302
Principal investigator 1 GENZYME CORPORATION $1,485.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141308
Principal investigator 1 GENZYME CORPORATION $1,430.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141310
Principal investigator 1 GENZYME CORPORATION $4,092.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141315
Principal investigator 1 GENZYME CORPORATION $14,550.01 12/15/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141317
Principal investigator 1 GENZYME CORPORATION $950.00 12/15/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141323
Principal investigator 1 Genentech, Inc. $875.00 12/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670554
Principal investigator 1 Genentech, Inc. $250.00 12/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670270
Principal investigator 1 TG Therapeutics, Inc. $3,655.00 12/11/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198487
Principal investigator 1 TG Therapeutics, Inc. $2,795.00 12/11/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199397
Principal investigator 1 TG Therapeutics, Inc. $51,744.15 12/09/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199385
Principal investigator 1 F. Hoffmann-La Roche AG $312.35 12/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670141
Principal investigator 1 Genentech, Inc. $2,506.00 12/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670557
Principal investigator 1 F. Hoffmann-La Roche AG $622.00 12/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670144
Principal investigator 1 F. Hoffmann-La Roche AG $51.00 12/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670169
Principal investigator 1 F. Hoffmann-La Roche AG $15.00 12/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670180
Principal investigator 1 F. Hoffmann-La Roche AG $10.00 12/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670188
Principal investigator 1 F. Hoffmann-La Roche AG $63.00 12/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670192
Principal investigator 1 F. Hoffmann-La Roche AG $29.00 12/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670208
Principal investigator 1 TG Therapeutics, Inc. $1,500.00 12/02/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198485
Principal investigator 1 TG Therapeutics, Inc. $763.25 12/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199395
Principal investigator 1 Novartis Pharmaceuticals Corporation $174,806.60 12/01/2025 Non-covered Recipient Entity
USF HEALTH UNIVERSITY OF SOUTH FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190301393
Principal investigator 1 Genentech, Inc. $4,380.00 11/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670266
Principal investigator 1 Genentech, Inc. $195.00 11/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670546
Principal investigator 1 Genentech, Inc. $7,018.00 11/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670708
Principal investigator 1 F. Hoffmann-La Roche AG $126.00 11/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670138
Principal investigator 1 F. Hoffmann-La Roche AG $168.00 11/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670148
Principal investigator 1 F. Hoffmann-La Roche AG $3,150.00 11/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670160
Principal investigator 1 F. Hoffmann-La Roche AG $117.00 11/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670165
Principal investigator 1 F. Hoffmann-La Roche AG $6,360.00 11/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670174
Principal investigator 1 F. Hoffmann-La Roche AG $3,150.00 11/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670176
Principal investigator 1 F. Hoffmann-La Roche AG $123.00 11/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670198
Principal investigator 1 Genentech, Inc. $200.00 11/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211670550
Principal investigator 1 GENZYME CORPORATION $21,642.35 11/17/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226080312
Principal investigator 1 Genentech, Inc. $7,832.00 11/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670533
Principal investigator 1 Genentech, Inc. $4,615.00 11/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670541
Principal investigator 1 Genentech, Inc. $1,540.00 11/13/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670716
Principal investigator 1 F. Hoffmann-La Roche AG $918.00 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670135
Principal investigator 1 F. Hoffmann-La Roche AG $11,196.00 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670157
Principal investigator 1 F. Hoffmann-La Roche AG $522.00 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670183
Principal investigator 1 F. Hoffmann-La Roche AG $180.00 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670204
Principal investigator 1 F. Hoffmann-La Roche AG $270.00 11/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670213
Principal investigator 1 TG Therapeutics, Inc. $10,482.85 11/10/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199393
Principal investigator 1 Genentech, Inc. $1,449.00 11/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211670538
Principal investigator 1 TG Therapeutics, Inc. $3,428.00 11/05/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198483
Principal investigator 1 TG Therapeutics, Inc. $3,202.32 11/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199553
Principal investigator 1 TG Therapeutics, Inc. $3,010.00 11/01/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198479
Principal investigator 1 TG Therapeutics, Inc. $18,306.00 11/01/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199383
Principal investigator 1 TG Therapeutics, Inc. $2,000.00 10/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199391
Principal investigator 1 Genentech, Inc. $650.00 10/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670258
Principal investigator 1 Genentech, Inc. $18,940.00 10/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670508
Principal investigator 1 Genentech, Inc. $38.00 10/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670526
Principal investigator 1 Genentech, Inc. $5,931.90 10/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670505
Principal investigator 1 Genentech, Inc. $20,350.20 10/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670513
Principal investigator 1 Genentech, Inc. $3,000.00 10/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670529
Principal investigator 1 Genentech, Inc. $1,987.00 10/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670522
Principal investigator 1 Genentech, Inc. $585.00 10/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670497
Principal investigator 1 Genentech, Inc. $1,750.00 10/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670501
Principal investigator 1 Genentech, Inc. $4,580.00 10/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670704
Principal investigator 1 GENZYME CORPORATION $3,475.00 10/14/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226124284
Principal investigator 1 Genentech, Inc. $760.00 10/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670517
Principal investigator 1 TG Therapeutics, Inc. $1,945.00 10/14/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199387
Principal investigator 1 TG Therapeutics, Inc. $4,391.85 10/14/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199389
Principal investigator 1 Genentech, Inc. $3,410.00 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670262
Principal investigator 1 Genentech, Inc. $14,825.00 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670691
Principal investigator 1 Genentech, Inc. $1,000.00 10/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670473
Principal investigator 1 Genentech, Inc. $5,483.33 10/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670448
Principal investigator 1 Genentech, Inc. $345.00 10/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670453
Principal investigator 1 TG Therapeutics, Inc. $710.00 10/06/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198481
Principal investigator 1 F. Hoffmann-La Roche AG $375.00 10/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670125
Principal investigator 1 F. Hoffmann-La Roche AG $650.00 10/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670131
Principal investigator 1 Genentech, Inc. $4,125.00 10/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670461
Principal investigator 1 Genentech, Inc. $4,050.00 10/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670469
Principal investigator 1 Genentech, Inc. $1,075.00 10/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670494
Principal investigator 1 TG Therapeutics, Inc. $57,965.20 09/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199499
Principal investigator 1 Genentech, Inc. $800.00 09/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670464
Principal investigator 1 F. Hoffmann-La Roche AG $3,150.00 09/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670075
Principal investigator 1 F. Hoffmann-La Roche AG $3,150.00 09/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670094
Principal investigator 1 F. Hoffmann-La Roche AG $3,150.00 09/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670107
Principal investigator 1 Genentech, Inc. $1,200.00 09/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670457
Principal investigator 1 Genentech, Inc. $1,223.00 09/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211670240
Principal investigator 1 Genentech, Inc. $5,273.00 09/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211670484
Principal investigator 1 Genentech, Inc. $3,952.00 09/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670678
Principal investigator 1 F. Hoffmann-La Roche AG $63.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670083
Principal investigator 1 F. Hoffmann-La Roche AG $29.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670086
Principal investigator 1 F. Hoffmann-La Roche AG $42.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670098
Principal investigator 1 F. Hoffmann-La Roche AG $7,669.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670102
Principal investigator 1 F. Hoffmann-La Roche AG $117.00 09/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670117
Principal investigator 1 TG Therapeutics, Inc. $88.56 09/12/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199509
Principal investigator 1 Genentech, Inc. $21,732.48 09/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211670244
Recipient TG Therapeutics, Inc. $807.35 09/08/2025 Covered Recipient Physician RMS302 No dispute reported 06/30/2026 1226197905
Principal investigator 1 TG Therapeutics, Inc. $4,710.00 09/08/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198457
Principal investigator 1 Genentech, Inc. $4,580.00 09/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670685
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 09/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199549
Principal investigator 1 TG Therapeutics, Inc. $6,020.00 08/31/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198515
Principal investigator 1 TG Therapeutics, Inc. $26,472.00 08/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199497
Principal investigator 1 TG Therapeutics, Inc. $1,745.00 08/28/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199507
Principal investigator 1 TG Therapeutics, Inc. $4,485.00 08/27/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199505
Principal investigator 1 Genentech, Inc. $11,088.00 08/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670488
Principal investigator 1 TG Therapeutics, Inc. $1,190.00 08/26/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198521
Principal investigator 1 TG Therapeutics, Inc. $4,485.00 08/26/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199503
Principal investigator 1 TG Therapeutics, Inc. $11,009.00 08/25/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198519
Principal investigator 1 Genentech, Inc. $8,975.00 08/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670477
Principal investigator 1 EMD Serono, Inc. $1,000.00 08/19/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118575
Principal investigator 1 EMD Serono, Inc. $1,000.00 08/19/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118577
Principal investigator 1 Genentech, Inc. $5,622.00 08/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670491
Principal investigator 1 Genentech, Inc. $9,460.00 08/13/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670253
Principal investigator 1 Genentech, Inc. $1,025.00 08/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670249
Principal investigator 1 Genentech, Inc. $254.00 08/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670682
Principal investigator 1 GENZYME CORPORATION $270.00 08/04/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141207
Principal investigator 1 GENZYME CORPORATION $3,456.00 08/04/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141213
Principal investigator 1 Genentech, Inc. $8,825.00 08/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211670445
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 08/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199547
Principal investigator 1 Genentech, Inc. $9,353.00 08/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670424
Principal investigator 1 Genentech, Inc. $1,370.00 08/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670432
Principal investigator 1 TG Therapeutics, Inc. $6,020.00 07/31/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198513
Principal investigator 1 TG Therapeutics, Inc. $9,340.00 07/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199495
Principal investigator 1 Genentech, Inc. $1,205.00 07/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670427
Principal investigator 1 Genentech, Inc. $2,182.00 07/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211670439
Principal investigator 1 GENZYME CORPORATION $1,091.34 07/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141210
Principal investigator 1 GENZYME CORPORATION $41,105.05 07/28/2025 Non-covered Recipient Entity
University Of South Florida
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141217
Principal investigator 1 F. Hoffmann-La Roche AG $317.02 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670070
Principal investigator 1 F. Hoffmann-La Roche AG $3,644.00 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670078
Principal investigator 1 F. Hoffmann-La Roche AG $832.21 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670089
Principal investigator 1 F. Hoffmann-La Roche AG $451.00 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670092
Principal investigator 1 F. Hoffmann-La Roche AG $150.00 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670111
Principal investigator 1 F. Hoffmann-La Roche AG $650.00 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670121
Principal investigator 1 Genentech, Inc. $1,420.00 07/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670673
Principal investigator 1 Genentech, Inc. $650.00 07/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670418
Principal investigator 1 Genentech, Inc. $690.00 07/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670442
Principal investigator 1 GENZYME CORPORATION $5,055.00 07/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141168
Principal investigator 1 GENZYME CORPORATION $8,438.28 07/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141171
Principal investigator 1 Genentech, Inc. $36,479.30 07/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670435
Principal investigator 1 Genentech, Inc. $4,580.00 07/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670660
Principal investigator 1 Genentech, Inc. $4,396.00 07/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS No dispute reported 06/30/2026 1211670235
Principal investigator 1 GENZYME CORPORATION $920.00 07/14/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141154
Principal investigator 1 GENZYME CORPORATION $1,045.00 07/14/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141157
Principal investigator 1 GENZYME CORPORATION $365.00 07/14/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141161
Principal investigator 1 GENZYME CORPORATION $920.00 07/14/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141164
Principal investigator 1 GENZYME CORPORATION $1,419.60 07/14/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141179
Principal investigator 1 GENZYME CORPORATION $55.18 07/14/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141204
Principal investigator 1 SANOFI US SERVICES INC. $650.00 07/14/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141198
Principal investigator 1 SANOFI US SERVICES INC. $260.00 07/14/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141201
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 07/14/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199545
Principal investigator 1 Genentech, Inc. $11,057.15 07/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670421
Principal investigator 1 Genentech, Inc. $254.00 07/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670667
Principal investigator 1 TG Therapeutics, Inc. $3,428.00 07/08/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198517
Principal investigator 1 TG Therapeutics, Inc. $6,255.50 07/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199501
Principal investigator 1 TG Therapeutics, Inc. $8,005.80 07/07/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199543
Principal investigator 1 GENZYME CORPORATION $15,994.40 07/02/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141147
Principal investigator 1 GENZYME CORPORATION $650.00 07/02/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141184
Principal investigator 1 SANOFI US SERVICES INC. $100.93 07/02/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141190
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 07/02/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141193
Principal investigator 1 Genentech, Inc. $230.00 06/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670215
Principal investigator 1 Genentech, Inc. $1,157.00 06/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670343
Principal investigator 1 Genentech, Inc. $21,766.00 06/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670592
Principal investigator 1 TG Therapeutics, Inc. $266.51 06/24/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199451
Principal investigator 1 GENZYME CORPORATION $5,260.25 06/23/2025 Non-covered Recipient Entity
University Of South Florida
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141151
Principal investigator 1 F. Hoffmann-La Roche AG $8,163.00 06/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670045
Principal investigator 1 F. Hoffmann-La Roche AG $8,163.00 06/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670050
Principal investigator 1 F. Hoffmann-La Roche AG $3,644.00 06/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670054
Principal investigator 1 Genentech, Inc. $293.00 06/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670350
Principal investigator 1 Genentech, Inc. $1,300.00 06/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670346
Principal investigator 1 Genentech, Inc. $562.00 06/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670575
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 06/12/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199493
Principal investigator 1 Genentech, Inc. $19,325.00 06/10/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670341
Principal investigator 1 Genentech, Inc. $650.00 06/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
First in human study RO7121932 No dispute reported 06/30/2026 1211670580
Principal investigator 1 TG Therapeutics, Inc. $965.00 06/06/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198511
Principal investigator 1 TG Therapeutics, Inc. $1,950.00 06/06/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199449
Principal investigator 1 Genentech, Inc. $5,078.00 06/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670355
Principal investigator 1 Genentech, Inc. $136.00 06/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670359
Principal investigator 1 TG Therapeutics, Inc. $85,128.00 06/01/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199447
Principal investigator 1 F. Hoffmann-La Roche AG $189.00 05/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670030
Principal investigator 1 F. Hoffmann-La Roche AG $3,644.00 05/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670038
Principal investigator 1 F. Hoffmann-La Roche AG $292.00 05/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670064
Principal investigator 1 F. Hoffmann-La Roche AG $189.00 05/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670066
Principal investigator 1 GENZYME CORPORATION $260.00 05/27/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141100
Principal investigator 1 GENZYME CORPORATION $55.18 05/27/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141105
Principal investigator 1 GENZYME CORPORATION $110.36 05/27/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141109
Principal investigator 1 GENZYME CORPORATION $650.00 05/27/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141114
Principal investigator 1 TG Therapeutics, Inc. $510.00 05/27/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198507
Principal investigator 1 TG Therapeutics, Inc. $390.00 05/27/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199431
Principal investigator 1 Genentech, Inc. $3,127.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670584
Principal investigator 1 Genentech, Inc. $1,540.00 05/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211670415
Principal investigator 1 Genentech, Inc. $32,562.00 05/13/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670225
Principal investigator 1 Novartis Pharmaceuticals Corporation $68,258.00 05/13/2025 Non-covered Recipient Entity
USF HEALTH
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190303949
Principal investigator 1 TG Therapeutics, Inc. $5,337.20 05/13/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199491
Principal investigator 1 GENZYME CORPORATION $25.00 05/12/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141137
Principal investigator 1 Genentech, Inc. $375.00 05/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670411
Principal investigator 1 SANOFI US SERVICES INC. $96.95 05/12/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141117
Principal investigator 1 SANOFI US SERVICES INC. $300.66 05/12/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141121
Principal investigator 1 Genentech, Inc. $419.00 05/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670230
Principal investigator 1 Genentech, Inc. $58,498.70 05/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670400
Principal investigator 1 TG Therapeutics, Inc. $86.34 05/07/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199445
Principal investigator 1 TG Therapeutics, Inc. $3,428.00 05/06/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198505
Principal investigator 1 TG Therapeutics, Inc. $5,977.50 05/06/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199429
Principal investigator 1 GENZYME CORPORATION $1,500.00 05/05/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141054
Principal investigator 1 Genentech, Inc. $4,326.00 05/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670396
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,486.56 04/30/2025 Non-covered Recipient Entity
Usf
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235992079
Principal investigator 1 GENZYME CORPORATION $325.00 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141042
Principal investigator 1 GENZYME CORPORATION $4,135.00 04/28/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141050
Principal investigator 1 GENZYME CORPORATION $55.18 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141056
Principal investigator 1 GENZYME CORPORATION $55.18 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141060
Principal investigator 1 GENZYME CORPORATION $55.18 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141067
Principal investigator 1 GENZYME CORPORATION $325.00 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141070
Principal investigator 1 GENZYME CORPORATION $25.00 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141074
Principal investigator 1 GENZYME CORPORATION $25.00 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141082
Principal investigator 1 GENZYME CORPORATION $455.00 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141086
Principal investigator 1 GENZYME CORPORATION $5,822.30 04/28/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141091
Principal investigator 1 Genentech, Inc. $5,006.00 04/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670651
Principal investigator 1 F. Hoffmann-La Roche AG $8,163.00 04/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670042
Principal investigator 1 F. Hoffmann-La Roche AG $8,163.00 04/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670058
Principal investigator 1 F. Hoffmann-La Roche AG $8,163.00 04/25/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670060
Principal investigator 1 UCB SA $39,800.00 04/23/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
A randomized, double-blind, placebo-controlled, multicenter, phase 3, pivotal study with an open-lable extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) No dispute reported 06/30/2026 1246659406
Recipient TG Therapeutics, Inc. $499.50 04/21/2025 Covered Recipient Physician RMS301 No dispute reported 06/30/2026 1226197903
Principal investigator 1 Genentech, Inc. $2,220.00 04/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670392
Principal investigator 1 Genentech, Inc. $650.00 04/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670403
Principal investigator 1 Genentech, Inc. $19,099.00 04/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211670408
Principal investigator 1 GENZYME CORPORATION $25.00 04/14/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141034
Principal investigator 1 GENZYME CORPORATION $11,259.00 04/14/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141047
Principal investigator 1 TG Therapeutics, Inc. $171.06 04/10/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199427
Principal investigator 1 GENZYME CORPORATION $740.00 04/02/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141022
Principal investigator 1 GENZYME CORPORATION $32.00 04/02/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141522
Recipient TG Therapeutics, Inc. $273.50 04/02/2025 Covered Recipient Physician RMS301 No dispute reported 06/30/2026 1226197897
Recipient TG Therapeutics, Inc. $1,159.23 04/02/2025 Covered Recipient Physician RMS301 No dispute reported 06/30/2026 1226197899
Recipient TG Therapeutics, Inc. $1,076.42 04/02/2025 Covered Recipient Physician RMS302 No dispute reported 06/30/2026 1226197901
Principal investigator 1 Genentech, Inc. $4,118.00 04/01/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670636
Principal investigator 1 TG Therapeutics, Inc. $1,300.00 03/31/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198503
Principal investigator 1 TG Therapeutics, Inc. $48,311.00 03/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199405
Principal investigator 1 TG Therapeutics, Inc. $375.00 03/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199423
Principal investigator 1 TG Therapeutics, Inc. $1,148.00 03/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199425
Principal investigator 1 TG Therapeutics, Inc. $26.78 03/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199443
Principal investigator 1 TG Therapeutics, Inc. $6,404.64 03/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199489
Principal investigator 1 TG Therapeutics, Inc. $1,275.00 03/26/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198501
Principal investigator 1 TG Therapeutics, Inc. $975.00 03/26/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199421
Principal investigator 1 GENZYME CORPORATION $375.00 03/24/2025 Non-covered Recipient Entity
University Of South Florida
Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141528
Principal investigator 1 F. Hoffmann-La Roche AG $3,420.00 03/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669966
Principal investigator 1 F. Hoffmann-La Roche AG $3,420.00 03/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669972
Principal investigator 1 F. Hoffmann-La Roche AG $3,644.00 03/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669981
Principal investigator 1 F. Hoffmann-La Roche AG $7,939.00 03/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669985
Principal investigator 1 F. Hoffmann-La Roche AG $292.00 03/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669994
Principal investigator 1 F. Hoffmann-La Roche AG $292.00 03/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670006
Principal investigator 1 F. Hoffmann-La Roche AG $8,163.00 03/21/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670009
Principal investigator 1 TG Therapeutics, Inc. $1,702.75 03/19/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199419
Principal investigator 1 GENZYME CORPORATION $34,451.35 03/17/2025 Non-covered Recipient Entity
University Of South Florida
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226140993
Principal investigator 1 GENZYME CORPORATION $4,545.00 03/17/2025 Non-covered Recipient Entity
University Of South Florida
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226140996
Principal investigator 1 GENZYME CORPORATION $27,900.00 03/17/2025 Non-covered Recipient Entity
University Of South Florida
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141000
Principal investigator 1 TG Therapeutics, Inc. $15,032.00 03/13/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199417
Principal investigator 1 F. Hoffmann-La Roche AG $252.00 03/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669990
Principal investigator 1 F. Hoffmann-La Roche AG $650.00 03/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669999
Principal investigator 1 F. Hoffmann-La Roche AG $218.04 03/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670002
Principal investigator 1 F. Hoffmann-La Roche AG $84.11 03/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670011
Principal investigator 1 F. Hoffmann-La Roche AG $272.61 03/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670023
Principal investigator 1 TG Therapeutics, Inc. $1,025.00 03/12/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199413
Principal investigator 1 TG Therapeutics, Inc. $6,679.50 03/12/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199415
Principal investigator 1 GENZYME CORPORATION $5,639.70 03/10/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141456
Principal investigator 1 TG Therapeutics, Inc. $15,050.00 02/28/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198495
Principal investigator 1 TG Therapeutics, Inc. $10,663.00 02/28/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199403
Principal investigator 1 GENZYME CORPORATION $607.50 02/24/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141014
Principal investigator 1 GENZYME CORPORATION $12,460.50 02/24/2025 Non-covered Recipient Entity
University Of South Florida
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141427
Principal investigator 1 Genentech, Inc. $10,423.00 02/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670373
Principal investigator 1 TG Therapeutics, Inc. $6,801.25 02/20/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199411
Principal investigator 1 GENZYME CORPORATION $62.30 02/18/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141517
Principal investigator 1 Genentech, Inc. $29,500.00 02/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA 3 No dispute reported 06/30/2026 1211670220
Principal investigator 1 Genentech, Inc. $4,580.00 02/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670599
Principal investigator 1 Genentech, Inc. $10,850.00 02/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670619
Principal investigator 1 TG Therapeutics, Inc. $244.75 02/17/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199409
Principal investigator 1 Genentech, Inc. $12,857.20 02/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211670369
Principal investigator 1 TG Therapeutics, Inc. $3,000.00 02/12/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198499
Principal investigator 1 GENZYME CORPORATION $3,456.00 02/10/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141460
Principal investigator 1 Genentech, Inc. $204.00 02/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670362
Principal investigator 1 Genentech, Inc. $41.91 02/07/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670387
Principal investigator 1 UCB SA $319.19 02/06/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
A randomized, double-blind, placebo-controlled, multicenter, phase 3, pivotal study with an open-lable extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) No dispute reported 06/30/2026 1246657630
Principal investigator 1 Genentech, Inc. $6,489.00 02/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670384
Principal investigator 1 TG Therapeutics, Inc. $3,736.04 02/03/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199487
Principal investigator 1 Novartis Pharmaceuticals Corporation $209,314.51 01/31/2025 Non-covered Recipient Entity
USF HEALTH MORSANI CENTER FOR ADVANCED HEALTHCARE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190303305
Principal investigator 1 TG Therapeutics, Inc. $48,229.00 01/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199401
Principal investigator 1 Novartis Pharmaceuticals Corporation $54,977.00 01/30/2025 Non-covered Recipient Entity
USF HEALTH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190303943
Principal investigator 1 TG Therapeutics, Inc. $27.91 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199435
Principal investigator 1 TG Therapeutics, Inc. $26.70 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199437
Principal investigator 1 TG Therapeutics, Inc. $34.71 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199439
Principal investigator 1 TG Therapeutics, Inc. $86.34 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199441
Principal investigator 1 Novartis Pharmaceuticals Corporation $116,543.00 01/28/2025 Non-covered Recipient Entity
USF HEALTH
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190303951
Principal investigator 1 TG Therapeutics, Inc. $1,955.00 01/28/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198497
Principal investigator 1 TG Therapeutics, Inc. $1,495.23 01/28/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199407
Principal investigator 1 EMD Serono, Inc. $520.00 01/27/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118573
Principal investigator 1 GENZYME CORPORATION $1,890.90 01/27/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226141451
Principal investigator 1 GENZYME CORPORATION $3,000.00 01/27/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141463
Principal investigator 1 GENZYME CORPORATION $4,588.75 01/27/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141467
Principal investigator 1 GENZYME CORPORATION $303.75 01/27/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141477
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 01/27/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199485
Principal investigator 1 GENZYME CORPORATION $5,291.66 01/24/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141435
Principal investigator 1 GENZYME CORPORATION $245.00 01/24/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141472
Principal investigator 1 F. Hoffmann-La Roche AG $7,939.00 01/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211669977
Principal investigator 1 F. Hoffmann-La Roche AG $3,420.00 01/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670016
Principal investigator 1 F. Hoffmann-La Roche AG $3,420.00 01/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211670019
Principal investigator 1 GENZYME CORPORATION $106.20 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141431
Principal investigator 1 GENZYME CORPORATION $110.36 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141448
Principal investigator 1 SANOFI US SERVICES INC. $104.32 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141345
Principal investigator 1 SANOFI US SERVICES INC. $102.40 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141349
Principal investigator 1 SANOFI US SERVICES INC. $215.80 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141361
Principal investigator 1 SANOFI US SERVICES INC. $102.87 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141367
Principal investigator 1 SANOFI US SERVICES INC. $100.94 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141370
Principal investigator 1 SANOFI US SERVICES INC. $6.45 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141375
Principal investigator 1 SANOFI US SERVICES INC. $130.70 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141379
Principal investigator 1 SANOFI US SERVICES INC. $418.17 01/21/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141383
Principal investigator 1 TG Therapeutics, Inc. $25.72 01/21/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199433
Principal investigator 1 Genentech, Inc. $4,649.00 01/17/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670603
Principal investigator 1 Genentech, Inc. $200.00 01/15/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab RMS High Dose Study No dispute reported 06/30/2026 1211670376
Principal investigator 1 Genentech, Inc. $152.00 01/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
OCARINA I No dispute reported 06/30/2026 1211670380
Principal investigator 1 Genentech, Inc. $1,300.00 01/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670607
Principal investigator 1 Genentech, Inc. $2,371.00 01/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Evaluation of Fenebrutinib in RMS patients II No dispute reported 06/30/2026 1211670629
Principal investigator 1 GENZYME CORPORATION $13,738.05 01/13/2025 Non-covered Recipient Entity
University Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226141011
Principal investigator 1 GENZYME CORPORATION $106.80 01/13/2025 Non-covered Recipient Entity
University Of South Florida
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226141026
Principal investigator 1 TG Therapeutics, Inc. $2,668.60 01/13/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199483
Principal investigator 1 UCB SA $1,320.00 01/13/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A randomized, double-blind, placebo-controlled, multicenter, phase 3, pivotal study with an open-lable extension period to evaluate the efficacy and safety of rozanolixizumab in adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD) No dispute reported 06/30/2026 1246657023
Principal investigator 1 Genentech, Inc. $1,326.00 01/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211670366
Principal investigator 1 SANOFI US SERVICES INC. $1,275.00 01/06/2025 Non-covered Recipient Entity
University Of South Florida
Long-term Extension Safety and Efficacy Study of SAR442168 in Participants With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226141019
Principal investigator 1 TG Therapeutics, Inc. $6,404.64 01/02/2025 Non-covered Recipient Entity
University of South Florida, USF Health Morsani Center for Advanced Healthcare
TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1226198509
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,329,380.84 01/01/2025 Non-covered Recipient Entity
USF HEALTH UNIVERSITY OF SOUTH FLORIDA
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190301395